AU2015269333B2 - Methods and compositions for treatment of disorders with follistatin polypeptides - Google Patents

Methods and compositions for treatment of disorders with follistatin polypeptides Download PDF

Info

Publication number
AU2015269333B2
AU2015269333B2 AU2015269333A AU2015269333A AU2015269333B2 AU 2015269333 B2 AU2015269333 B2 AU 2015269333B2 AU 2015269333 A AU2015269333 A AU 2015269333A AU 2015269333 A AU2015269333 A AU 2015269333A AU 2015269333 B2 AU2015269333 B2 AU 2015269333B2
Authority
AU
Australia
Prior art keywords
polypeptide
amino acid
acid sequence
seq
follistatin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2015269333A
Other languages
English (en)
Other versions
AU2015269333A1 (en
Inventor
Asya Grinberg
Ravindra Kumar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Acceleron Pharma Inc
Original Assignee
Acceleron Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acceleron Pharma Inc filed Critical Acceleron Pharma Inc
Publication of AU2015269333A1 publication Critical patent/AU2015269333A1/en
Application granted granted Critical
Publication of AU2015269333B2 publication Critical patent/AU2015269333B2/en
Priority to AU2020210315A priority Critical patent/AU2020210315A1/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4707—Muscular dystrophy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2015269333A 2014-06-04 2015-06-04 Methods and compositions for treatment of disorders with follistatin polypeptides Ceased AU2015269333B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2020210315A AU2020210315A1 (en) 2014-06-04 2020-08-03 Methods and compositions for treatment of disorders with follistatin polypeptides

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462007908P 2014-06-04 2014-06-04
US62/007,908 2014-06-04
PCT/US2015/034245 WO2015187977A1 (en) 2014-06-04 2015-06-04 Methods and compositions for treatment of disorders with follistatin polypeptides

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2020210315A Division AU2020210315A1 (en) 2014-06-04 2020-08-03 Methods and compositions for treatment of disorders with follistatin polypeptides

Publications (2)

Publication Number Publication Date
AU2015269333A1 AU2015269333A1 (en) 2016-12-15
AU2015269333B2 true AU2015269333B2 (en) 2020-05-07

Family

ID=54767384

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2015269333A Ceased AU2015269333B2 (en) 2014-06-04 2015-06-04 Methods and compositions for treatment of disorders with follistatin polypeptides
AU2020210315A Abandoned AU2020210315A1 (en) 2014-06-04 2020-08-03 Methods and compositions for treatment of disorders with follistatin polypeptides

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2020210315A Abandoned AU2020210315A1 (en) 2014-06-04 2020-08-03 Methods and compositions for treatment of disorders with follistatin polypeptides

Country Status (12)

Country Link
US (2) US10023621B2 (enExample)
EP (2) EP3152237B1 (enExample)
JP (3) JP6568110B2 (enExample)
KR (4) KR102132144B1 (enExample)
CN (2) CN106795224B (enExample)
AU (2) AU2015269333B2 (enExample)
BR (1) BR112016028520A2 (enExample)
CA (1) CA2950754C (enExample)
EA (2) EA202090632A1 (enExample)
MA (2) MA51074A (enExample)
MX (2) MX382908B (enExample)
WO (1) WO2015187977A1 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0618947B1 (pt) 2005-11-23 2022-07-19 Acceleron Pharma Inc Polipeptídeo actriia que se liga à ativina, polinucleotídeo isolado, polinucleotídeo recombinante, métodopara preparar um polipeptídeo actriia que se liga à ativina, preparação farmacêutica e uso de uma proteína de fusão actriia-fc para promover o crescimento ósseo e inibir a ressorção óssea
EP2315602A4 (en) 2008-06-26 2011-11-02 Acceleron Pharma Inc METHOD OF DOSING AN ACTRIIB ANTAGONIST AND MONITORING TREATED PATIENTS
CA2898121A1 (en) 2013-01-25 2014-07-31 Shire Human Genetic Therapies, Inc. Follistatin in treating duchenne muscular dystrophy
US10010498B2 (en) 2014-06-04 2018-07-03 Acceleron Pharma Inc. Methods for treatment of amyotrophic lateral sclerosis with follistatin fusion proteins
JP6568110B2 (ja) 2014-06-04 2019-08-28 アクセルロン ファーマ， インコーポレイテッド フォリスタチンポリペプチドによる障害の処置のための方法および組成物
CN114699529A (zh) 2014-06-13 2022-07-05 阿塞勒隆制药公司 用于治疗溃疡的方法和组合物
CA2980757A1 (en) 2015-03-26 2016-09-29 Acceleron Pharma Inc. Follistatin-related fusion proteins and uses thereof
BR112018067747A2 (pt) * 2016-03-04 2019-01-08 Shire Human Genetic Therapies proteínas de fusão recombinantes de folistatina-fc e uso no tratamento da distrofia muscular de duchenne
US10905766B2 (en) 2017-03-23 2021-02-02 Oregon State University Therapeutic compositions and methods for treatment of muscle wasting diseases
KR101822633B1 (ko) * 2017-08-22 2018-01-26 (주)진셀팜 폴리스타틴 유래 생리활성 펩타이드, 및 이의 용도
WO2019046903A1 (en) * 2017-09-08 2019-03-14 Baker Heart and Diabetes Institute THERAPEUTIC METHOD FOR INCREASING MUSCLE MASS IN A SUBJECT
CN108218985B (zh) * 2017-12-12 2021-04-30 山西农业大学 一种利用特征多肽制备fst蛋白特异性抗体的方法及其应用
CA3093716A1 (en) * 2018-03-16 2019-09-19 Immusoft Corporation B cells genetically engineered to secrete follistatin and methods of using the same to treat follistatin-related diseases, conditions, disorders and to enhance muscle growth and strength
US11672845B2 (en) * 2018-03-21 2023-06-13 Soulyoung Biotech Co., Ltd. Composition for promoting local muscle growth or slowing down or preventing local muscle atrophy and use thereof
WO2019191204A1 (en) * 2018-03-28 2019-10-03 Acceleron Pharma Inc. Follistatin polypeptides for the treatment of muscle contracture
AU2019269702A1 (en) * 2018-05-17 2020-12-24 Housey Pharmaceutical Research Laboratories, L.L.C. Inhibition of follistatin
US12246042B2 (en) 2018-08-29 2025-03-11 Myos Corp. Methods for alleviating, inhibiting or reversing muscle disuse atrophy in mammals
US12508262B2 (en) 2020-04-30 2025-12-30 Keros Therapeutics, Inc. Methods of using ALK2 inhibitors
WO2022098812A1 (en) 2020-11-04 2022-05-12 Keros Therapeutics, Inc. Methods of treating iron overload
AU2022214780A1 (en) * 2021-01-26 2023-09-07 Immunis, Inc. Molecular superstructure and methods of use thereof
KR20250024825A (ko) 2022-06-15 2025-02-19 유씨비 바이오파마 에스알엘 폴리스타틴-fc 융합 단백질
CA3259309A1 (en) 2022-06-15 2023-12-21 UCB Biopharma SRL Fusion protein for the prevention, treatment or improvement of kidney disease
EP4630443A1 (en) * 2022-12-07 2025-10-15 Kamino ApS Extracellular matrix binding compounds for the localized loading of therapeutic or diagnostic agents
KR102971166B1 (ko) * 2022-12-09 2026-06-01 (주)케어젠 연골 재생용 펩타이드 및 이의 용도
TW202530250A (zh) * 2024-01-25 2025-08-01 大陸商四川至善唯新生物科技有限公司 編碼卵泡抑素的核酸及其用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110070233A1 (en) * 2009-09-09 2011-03-24 Acceleron Pharma Inc. Actriib antagonists and dosing and uses thereof
WO2014116981A1 (en) * 2013-01-25 2014-07-31 Shire Human Genetic Therapies, Inc. Follistatin in treating duchenne muscular dystrophy
WO2014187807A1 (en) * 2013-05-21 2014-11-27 Arcarios B.V. Follistatin derivatives

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63502716A (ja) 1986-03-07 1988-10-13 マサチューセッツ・インステチュート・オブ・テクノロジー 糖タンパク安定性の強化方法
US5041538A (en) 1987-08-28 1991-08-20 The Salk Institute For Biological Studies Mammalian follistatin
US5182375A (en) 1987-08-28 1993-01-26 The Salk Institute For Biological Studies DNA encoding follistatin
DE69233480T2 (de) 1991-02-08 2006-01-05 Progenics Pharmaceuticals, Inc. CD4-gamma2- und CD4-IgG2-Chimären
EP0661993B1 (en) 1992-09-16 1997-05-07 Genentech, Inc. Protection against liver damage by hgf
DE69434934D1 (de) 1993-10-14 2007-04-12 Harvard College Verfahren zur induzierung und zur erhaltung neuronalen zellen
US6686198B1 (en) 1993-10-14 2004-02-03 President And Fellows Of Harvard College Method of inducing and maintaining neuronal cells
US5541087A (en) 1994-09-14 1996-07-30 Fuji Immunopharmaceuticals Corporation Expression and export technology of proteins as immunofusins
US5545616A (en) 1994-09-22 1996-08-13 Genentech, Inc. Method for predicting and/or preventing preterm labor
GB2306481A (en) 1995-10-21 1997-05-07 Univ Manchester Pharmaceutical comprising a stimulator of activin and/or inhibin
WO1999006559A1 (en) 1997-08-01 1999-02-11 The Johns Hopkins University School Of Medicine Methods to identify growth differentiation factor (gdf) receptors
US6891082B2 (en) 1997-08-01 2005-05-10 The Johns Hopkins University School Of Medicine Transgenic non-human animals expressing a truncated activintype II receptor
US6656475B1 (en) 1997-08-01 2003-12-02 The Johns Hopkins University School Of Medicine Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same
US6004937A (en) 1998-03-09 1999-12-21 Genetics Institute, Inc. Use of follistatin to modulate growth and differentiation factor 8 [GDF-8] and bone morphogenic protein 11 [BMP-11]
JP2003517580A (ja) 1999-01-21 2003-05-27 メタモーフイクス・インコーポレーテツド 増殖分化因子インヒビター及びそれらの用途
CA2365449A1 (en) 1999-04-19 2000-10-26 Kyowa Hakko Kogyo Co., Ltd. Inhibitor of the growth of androgen-independent tumor
WO2001009368A1 (en) 1999-07-30 2001-02-08 The General Hospital Corporation Follistatin antagonists
JP4487376B2 (ja) 2000-03-31 2010-06-23 味の素株式会社 腎疾患治療剤
AUPR638101A0 (en) 2001-07-13 2001-08-09 Bioa Pty Limited Composition and method for treatment of disease
BR0307907A2 (pt) 2002-02-21 2011-07-05 Wyeth Corp gasp1: proteìna contendo domìnio de folistatina
CN1993048A (zh) * 2002-02-21 2007-07-04 惠氏公司 包含促滤泡素抑制素结构域的蛋白质
PL374966A1 (en) 2002-02-21 2005-11-14 Wyeth Follistatin domain containing proteins
WO2004082710A1 (en) 2003-03-21 2004-09-30 Lorantis Limited Treatment of allergic diseases using a modulator of the notch signaling pathway
WO2004108157A2 (en) 2003-06-02 2004-12-16 Wyeth Use of myostatin (gdf8) inhibitors in conjunction with corticosteroids for treating neuromuscular disorders
WO2005025601A1 (en) 2003-09-15 2005-03-24 Monash University Follistatin isoforms and uses thereof
US7355018B2 (en) 2003-09-30 2008-04-08 Regeneron Pharmaceuticals, Inc. Modified IGF1 polypeptides with increased stability and potency
WO2005032578A1 (en) 2003-10-06 2005-04-14 Monash University Therapeutic method
JP4688483B2 (ja) 2004-04-15 2011-05-25 株式会社テクノネットワーク四国 フォリスタチン変異体ポリペプチド
JP2008507288A (ja) * 2004-07-23 2008-03-13 アクセルロン ファーマ インコーポレーテッド ＡｃｔＲＩＩ受容体ポリペプチド、方法、および組成物
MX2007000976A (es) 2004-08-12 2007-04-10 Wyeth Corp Tratamiento combinado para diabetes, obesidad y enfermedades cardiovasculares utilizando inhibidores del factor 8 de crecimiento y diferenciacion.
NZ538097A (en) 2005-02-07 2006-07-28 Ovita Ltd Method and compositions for improving wound healing
US7888486B2 (en) 2005-08-19 2011-02-15 Wyeth Llc Antagonist antibodies against GDF-8
US20070149458A1 (en) * 2005-12-06 2007-06-28 Amgen Inc. Uses of myostatin antagonists
WO2008030367A2 (en) 2006-09-01 2008-03-13 The General Hospital Corporation Selective myostatin inhibitors
WO2008067480A2 (en) 2006-11-29 2008-06-05 Nationwide Children's Hospital Myostatin inhibition for enhancing muscle and/or improving muscle function
CA2672758C (en) 2006-12-18 2019-07-30 Acceleron Pharma Inc. Activin-actrii antagonists and uses for increasing red blood cell levels
US20100028332A1 (en) 2006-12-18 2010-02-04 Acceleron Pharma Inc. Antagonists of actriib and uses for increasing red blood cell levels
US8895016B2 (en) 2006-12-18 2014-11-25 Acceleron Pharma, Inc. Antagonists of activin-actriia and uses for increasing red blood cell levels
EP3663318A1 (en) 2008-01-07 2020-06-10 Amgen Inc. Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
EP2315602A4 (en) * 2008-06-26 2011-11-02 Acceleron Pharma Inc METHOD OF DOSING AN ACTRIIB ANTAGONIST AND MONITORING TREATED PATIENTS
KR20110031951A (ko) * 2008-06-26 2011-03-29 악셀레론 파마 인코포레이티드 액티빈-ａｃｔｒｉｉａ의 길항물질 및 적혈구 수준을 증가시키기 위한 이들의 용도
KR101603001B1 (ko) * 2010-08-25 2016-03-11 에프. 호프만-라 로슈 아게 Il-18r1에 대한 항체 및 그의 용도
CN103429620B (zh) 2010-11-05 2018-03-06 酵活有限公司 在Fc结构域中具有突变的稳定异源二聚的抗体设计
WO2013151664A1 (en) * 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of proteins
ES2663993T3 (es) 2012-05-17 2018-04-17 Paranta Biosciences Limited Uso de folistatina o de un inhibidor de activina para prevenir o tratar la disfunción del injerto de tejido
EP2866826B1 (en) * 2012-06-27 2025-08-06 Meiragtx UK II Limited Combination for treating an inflammatory disorder
US10010498B2 (en) 2014-06-04 2018-07-03 Acceleron Pharma Inc. Methods for treatment of amyotrophic lateral sclerosis with follistatin fusion proteins
JP6568110B2 (ja) 2014-06-04 2019-08-28 アクセルロン ファーマ， インコーポレイテッド フォリスタチンポリペプチドによる障害の処置のための方法および組成物
CA2980757A1 (en) 2015-03-26 2016-09-29 Acceleron Pharma Inc. Follistatin-related fusion proteins and uses thereof
AU2018266893A1 (en) 2017-05-12 2019-12-05 Takeda Pharmaceutical Company Limited Recombinant follistatin-Fc fusion proteins and use in treating Duchenne muscular dystrophy

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110070233A1 (en) * 2009-09-09 2011-03-24 Acceleron Pharma Inc. Actriib antagonists and dosing and uses thereof
WO2014116981A1 (en) * 2013-01-25 2014-07-31 Shire Human Genetic Therapies, Inc. Follistatin in treating duchenne muscular dystrophy
WO2014187807A1 (en) * 2013-05-21 2014-11-27 Arcarios B.V. Follistatin derivatives

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Cash, J. et al. 2012 Mol Endocrinol, Vol. 26, no. 7, pp.1167-1178 *
Datta-Mannan, A. et al. 2013 J Pharmacol Exp Ther, Vol. 344, pp. 616-623 *
Yaden, B. et al. 2014, J Pharmacol Exp Ther, Vol. 349, pp. 355-371 *

Also Published As

Publication number Publication date
CA2950754C (en) 2021-10-26
US10954279B2 (en) 2021-03-23
KR102077286B1 (ko) 2020-02-13
JP2019203017A (ja) 2019-11-28
CN113583104A (zh) 2021-11-02
KR20200017548A (ko) 2020-02-18
US20180340013A1 (en) 2018-11-29
JP6568110B2 (ja) 2019-08-28
KR20200084064A (ko) 2020-07-09
MX2021006017A (es) 2021-07-06
MX2016015868A (es) 2017-04-05
EA035455B1 (ru) 2020-06-18
JP6856716B2 (ja) 2021-04-07
JP2021095416A (ja) 2021-06-24
EP3152237B1 (en) 2020-04-01
KR102132144B1 (ko) 2020-07-09
KR20170005891A (ko) 2017-01-16
US20160185836A1 (en) 2016-06-30
AU2015269333A1 (en) 2016-12-15
MA51074A (fr) 2020-10-14
CN106795224B (zh) 2021-05-18
JP2017518303A (ja) 2017-07-06
EP3721892A1 (en) 2020-10-14
MA51075A (fr) 2020-10-14
BR112016028520A2 (pt) 2017-10-24
CN106795224A (zh) 2017-05-31
MX382908B (es) 2025-03-13
EA201692529A1 (ru) 2017-05-31
EP3152237A4 (en) 2017-11-01
WO2015187977A1 (en) 2015-12-10
AU2020210315A1 (en) 2020-08-27
EP3721892B1 (en) 2024-05-22
US10023621B2 (en) 2018-07-17
CA2950754A1 (en) 2015-12-10
KR102305109B1 (ko) 2021-09-27
EP3152237A1 (en) 2017-04-12
EA202090632A1 (ru) 2020-07-31
KR20210119546A (ko) 2021-10-05

Similar Documents

Publication Publication Date Title
US10954279B2 (en) Methods and compositions for treatment of disorders with follistatin polypeptides
US11497792B2 (en) Methods for treatment of Duchenne muscular dystrophy with follistatin polypeptides
US20220169996A1 (en) Truncated actriib-fc fusion proteins
DK2332977T3 (en) ActRII receptor polypeptides
EP3293198B1 (en) Variants derived from actriib and uses therefor
WO2019191204A1 (en) Follistatin polypeptides for the treatment of muscle contracture
HK1236544A1 (en) Methods and compositions for treatment of disorders with follistatin polypeptides
HK1236544B (en) Methods and compositions for treatment of disorders with follistatin polypeptides
HK1238658A1 (en) Methods and compositions for treatment of disorders with follistatin polypeptides
HK1238658B (en) Methods and compositions for treatment of disorders with follistatin polypeptides

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired